Skip to main content
    T

    Thermo Fisher Scientific Inc (TMO)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $691.77
    -8.45 (-1.21%)

    Market Cap: $259.44B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Thermo Fisher Scientific Inc (TMO) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Thermo Fisher Scientific (TMO) trades at 28.0x trailing earnings and 5.4x sales. Its P/E of 28.0x is above its 5-year median of 24.1x. Its forward P/E is 25.1x. The median P/E across 11 similar companies is 28.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 11.6% higher over the next year. Its free cash flow yield is 3.0%.

    MultipleValue
    P/E (trailing)28.0x
    Forward P/E25.1x
    Price to sales5.4x
    Price to book4.7x
    EV/EBITDA25.2x
    Price to FCF33.7x
    EV/FCF38.4x
    PEG2.0
    FCF yield3.0%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 19.7% above 23.4x, its P/S is 12.5% above 4.8x and its P/B is 9.3% above 4.3x.

    MultipleCurrent5-year median10-year median
    P/E28.0x24.1x23.4x
    P/S5.4x4.9x4.8x
    P/B4.7x4.6x4.3x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 17.1x in 2016 to 26.6x in 2021.

    Year endPriceP/EP/SP/B
    2025$579.4525.3x4.9x4.1x
    2024$520.2323.8x4.6x4.0x
    2023$530.7924.6x4.8x4.4x
    2022$550.6923.7x4.8x4.9x
    2021$667.2426.6x6.7x6.5x
    2020$465.7823.8x5.7x5.4x
    2019$324.8726.3x5.1x4.4x
    2018$223.7920.1x3.7x3.3x
    2017$189.8820.0x3.6x3.0x
    2016$141.1017.1x3.1x2.6x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TMO

    What is TMO's forward P/E ratio?

    Thermo Fisher Scientific has a forward P/E ratio of 25.1x.

    Is TMO stock overvalued?

    GNG's valuation label for TMO is Fairly valued. Its P/E of 28.0x compares with a median of 28.5x across 11 similar companies.

    What is TMO's price to sales ratio?

    Thermo Fisher Scientific has a price to sales ratio of 5.4x.

    What is Thermo Fisher Scientific's average P/E ratio over 5 years?

    Thermo Fisher Scientific's median P/E over the last 5 years is 24.1x, from 60 month-end values through Oct 2026.

    What is TMO's PEG ratio?

    Thermo Fisher Scientific has a PEG ratio of 2.0.